The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma

Abstract

Objective. To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. Methods. Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, n = 27) or axitinib combined with tislelizumab (study group, n = 22). The clinical efficacy, renal function and adverse reactions were compared between the two groups. Results. After treatment, both groups showed a significant decrease in blood urea nitrogen (BUN) and serum creatinine (SCR), but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05 ). After treatment, both groups showed a significant decrease in TNF-β1, VEGF, TIMP-1, and MMP-2, but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05 ). The study group had significantly higher rates of adverse reactions ( p < 0.05 ). Significant difference was observed in ORR (59.1% vs 40.7%) and DCR (81.8% vs 66.7%) between the study group and the control group, with higher results in study group ( p < 0.05 ). The study group was superior to the control group in OS ( p < 0.05 ). Conclusion. Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects.

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review

“…A retrospective study in 2022 showed that Tislelizumab plus Axitinib significantly increased ORR (59.1% vs. 40.7%) and DCR (81.8% vs. 66.7%) in patients with advanced renal clear cell carcinoma compared with acitinib monotherapy. 20 However, there are limited clinical data on the efficacy of Tislelizumab in patients with mccRCC. Further observation and accumulation of more experience are needed to conduct further clinical studies on the efficacy and safety of this combination regimen.…”

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report

“…showed significant differences in the objective response rate (59.1% vs. 40.7%) and disease control rate (81.8% vs. 40.7%) between axitinib combined with tislelizumab and axitinib alone in advanced renal carcinoma. Moreover, the combined treatment group exhibited higher overall survival (median overall survival 8.9 months vs. 5.8 months) ( 35 ). In our case, after diagnosing the patient with TFE3 -rearranged RCC, considering the patient’s young age and presence of metastases, the prognosis was expected to be poor.…”